Invention Grant
- Patent Title: Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
-
Application No.: US15988790Application Date: 2018-05-24
-
Publication No.: US10351571B2Publication Date: 2019-07-16
- Inventor: Stephanos Ioannidis , Adam Charles Talbot , Bruce Follows , Alexandre Joseph Buckmelter , Minghua Wang , Ann-Marie Campbell
- Applicant: FORMA Therapeutics, Inc.
- Applicant Address: US MA Watertown
- Assignee: FORMA Therapeutics, Inc.
- Current Assignee: FORMA Therapeutics, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Choate, Hall & Stewart LLP
- Agent Michael A. Shinall; Nicholas J. Pace
- Main IPC: C07D487/04
- IPC: C07D487/04
Abstract:
The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, X1, X2, m, and n are described herein.
Public/Granted literature
- US20180339991A1 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Public/Granted day:2018-11-29
Information query
